Biotek-snakken — Juli 2022
-
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivativ
Yahoo Finance (finance.yahoo.com)
-
Er der nogle herinde der følger Horizon Therapeutics (HZNP)? Jeg har over årerne øget min investering i selskabet. De er godt ledet og gør det godt inden for deres speciale - sjældne, autoimmune og inflammatoriske sygdomme. Den har sat sig noget de seneste måneder, men på nøgletal fremstår casen virkelig god. Det overrasker mig lidt de ikke er blevet belønnet for deres label udvidelsen på KRYSTEXXA (også selvom den var forventet). Jeg er spændt på hvad de guider i deres kvartals aflæggelse 3.
-
Så kom Carnegie lige på købersiden i XBrane til sidst
Vi er på rette vej igen… Carnegie Investment Bank AB 8.946 0 +8.946 -
2 Biotech Stocks That Could Help Make You a Fortune
https://www.proinvestor.com/investornyt/858431/2-biotech-stocks-that-could-help-make-you-a-fortune -
Biovica receives FDA approval for DiviTum
TKa https://biovica.com/mfn_news/biovica-receives-fda-approval-for-divitumtka/ -
Biovica…Red Eye… The company is now likely to graduate into a revenue company in H2 2022. Our value proposition is a base case value of SEK 95 (Bull SEK 325, Bear SEK 20). https://www.redeye.se/research/839982/biovica-fda-submission-goal-in-sight
-
Burde give en pæn stigning til Biovica
….usikkerheden er ny ryddet af vejen, men vi får se We will now intensify our efforts to make DiviTumTKa available for the benefit of breast cancer patients in USA before the end of this year,” said Anders Rylander CEO of Biovica. -
Fra marts 2022…de er kørt i stilling:
Biovica etablerar amerikanskt CLIA-labb för att förstärka lanseringen av DiviTumTKaBiovica, verksamt inom cancerdiagnostik, meddelar idag att bolaget kommer att etablera ett eget CLIA-labb för lanseringen av DiviTum
TKa på den amerikanska marknaden. Biovica siktar på att labbet blir CLIA-ackrediterat och operativt under tredje kvartalet 2022. -
Jazz…tænker da, hvis den kan købes imorgen under kurs 40, så vil jeg supplere….har kun et frimærke idag, da det var stor risiko….nu er noget af risikoen væk og vil derfor supplere op til en pakkelabel istedetfor
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind